EDEN PRAIRIE, Minn., Aug. 29, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today it has added six seasoned sales professionals to its commercial sales organization to better serve its customer demand. The new sales representatives joined CHF Solutions from top tiered medical device organizations and bring deep levels of expertise and market development success. CHF Solutions has implemented a best-in-class clinical and sales training program designed to drive sales productivity and account conversion within its growing sales organization. The newly hired sales professionals will focus on enhancing
existing account penetration, and on new business development.
"We are excited to continue our sales team expansion with the onboarding of six new, deeply experienced sales representatives who will aid in the accomplishment of our growth goals," said John Erb, Chairman and CEO. "We have established a comprehensive sales training program to optimize time to productivity for our new sales representatives in support of our commercial strategy," Mr. Erb added.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed
diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ
Capital Market since February 2012.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the focus of the newly hired sales professional on enhancing existing account penetration and new business development, and that sales representatives will aid in the accomplishment of our growth goals. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our
ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
516 222 2560
CHF Solutions, Inc.
Source: CHF Solutions
News Provided by Acquire Media